Positive top-line results from Phase 3 study of ABRYSVO® in adults aged 18 to 59 at increased risk for RSV Disease
Pfizer announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness), evaluating a single dose of ABRYSVO versus placebo in adults 18 to 59 years…